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SUMMARY 
Objective: To study maternal and fetal outcomes in Ghanaian women with systemic lupus erythematosus (SLE). 
Methods: Retrospective study of pregnancies in women with SLE in a single centre in Ghana. 
Results: The mean age was 30.1 years and all were nulliparous. Two out of the seven pregnancies were in disease 
remission at the time of booking. Nephritis without renal impairment was present in 7 pregnancies (6 women).  One 
woman developed intrapartum eclampsia. Two women had secondary antiphospholipid syndrome (APS). Two suf-
fered early fetal losses and one late fetal loss at 32 weeks.  All three who lost their fetus had uncontrolled hyperten-
sion. Six had mild flares mainly joint pains during pregnancy. There was no maternal mortality.  The median gesta-
tional age at delivery was 38 weeks (range, 16 to 40 weeks) and the mean birth weight was 3017 g; the median Ap-
gar scores were 8 and 9 at 1 and 5 minutes of life, respectively. There were no cases of intrauterine growth re-
striction (IUGR). There were no cases of congenital heart block or neonatal lupus.  
Conclusion: Good pregnancy outcomes are possible in women with SLE even in resource poor settings. . All preg-
nancies should still be considered high risk and be managed jointly between the obstetricians, the perinatologists and 
the rheumatologists, in particular, those with renal involvement and hypertension. Long term follow up of a larger 
cohort is needed. 
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INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is predominantly 
a disease of women and it tends to affect women during 
their childbearing years.1  Worldwide there is a higher 
incidence in people of African descent.2  Over the years 
there has been an improvement in the life expectancy 
and quality of life of patients with SLE due to im-
provements and new innovations in disease manage-
ment.  
 
Fertility in SLE patients is generally comparable to the 
general population, though in the past, patients with 
SLE were discouraged from getting pregnant by doctors 
not familiar with the disease and its management with 
the fear that pregnancy might worsen disease outcome.  
With careful management and better disease control, 
maternal and fetal outcomes have improved and preg-
nancy is no longer contraindicated but is still associated 
with high risks.2 
 
Adverse fetal outcomes such as increase pregnancy loss, 
intrauterine growth restriction, preterm delivery have 
also been documented.3 For those with renal involve-
ment, successful outcome of pregnancy may be ex-
pected even in the more severe forms of lupus nephritis 
if gestation begins after a persistent clinical remission, 
usual recommendation being up to six to 12 months of 
stable disease activity.4 Both lupus nephritis and anti-
phospholipid antibodies increase the risks for maternal 
hypertension and premature births.5 Therefore, the cur-
rent evidence supports timing of pregnancy relative to 
SLE activity and multispecialty care of these patients.6 
SLE is reported to be rare in sub-Saharan Africa7 ,8 and 
so most physicians and obstetricians may not be familiar 
with the management of cases, though clinical audits 
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Due to the tendency of SLE to affect women in their 
childbearing year’s and the likelihood of more pregnan-
cies occurring in these group of patients, we report on 
the outcomes of pregnant SLE women who were  man-
aged  at the Korle Bu Teaching Hospital.  
 
METHODS 
Patients who were diagnosed to have SLE using clinical 
and laboratory criteria in keeping with American Col-
lege of Rheumatology (ACR) criteria11 and had been 
pregnant over the preceding year( i.e. between the year 
2013-2014) had their data collected retrospectively. 
 
The patients had all been all under the care of the 
Rheumatologist and the Obstetricians at the Korle bu 
Teaching Hospital and were subject to usual care and or 
more frequent reviews as dictated by their conditions. 
The data were analysed by their demographic character-
istics, clinical and serology features and laboratory ab-
normalities including the presence of abnormalities of 
urinary sediment. Treatment during pregnancy, the out-
come of the pregnancy and the state of the baby was 
also documented. Risks of adverse pregnancy outcomes 
and disease flares were identified. 
 
RESULTS 
A total of seven pregnancies in six SLE patients with a 
mean age of 30.1 years (age range 27 to 32) were fol-
lowed up until the end of their pregnancies. Only two 
were in clinical remission before they got pregnant. 
 
Six of these patients complained of joint pains and on 
examination had skin lesions during their pregnancy. 
Three of the patients had elevated blood pressure, which 
remained raised in spite of treatment with antihyperten-
sive drugs. The highest blood pressure measured was 
160/100mmHg. 
 
Table 1 Laboratory results  















ANA 1:640 Positive Positive 1:320 1:640 Negative 1:320 
Anti-ds DNA Positive  + Positive 1:40 1:80 Not done Negative 
Anti Sm Positive  + Positive Not done Not done Not done Not done 
Anti Ro Negative Not done Positive Not done Not done Not done Not done 
Anti La Negative Not done Positive Not done Not done Not done Not done 
Antiphospholipid syndrome Positive Positive Not done Not done Positive Not done Negative 
Complement C3 (83-193) Not done 96 88 97 84 78 Not done 
Complement C4 (15-57) Not done 42 45 27 Not done Not done Not done 
Urine protein 3+ 1+ Not done 3+ 1+ 3+ Trace 
Urine red blood cells Negative Trace Not done 3+ 2+ 3+ Negative 
Haemoglobin g/dl 10. 11.3 13.3 9.9 11.0 10.5 10.8 
WBC  5.9 3.3 5.1 6.9 6.3 6.4 6.1 
Platelets 347 229 176 386 168 89 71 
ESR 116 64 Not done 132 57 Not done Not done 
Urea (2.5- 7.5mmol/l) 2.1 3.7 6.9 6.6 3.7 3.6 3.2 
Creatinine (40-110 umol/l) 31 62 47 142 83 69 64 
Urine albumin creatinine ratio  (0.0 – 2.9) Not done 40.24 49.75 77.10 4.07 671.0 Not done 
Renal biopsy Not done Not done Lupus 
nephritis 3 
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Laboratory results 
Laboratory results are shown in Table 1. Antinuclear 
antibodies (ANA) were tested in all six of the patients. 
The titre was elevated in five out of the six patients 
ranging from 1:320 to 1:640 and negative in one patient. 
 
Antibody to double stranded DNA, (Anti ds DNA) was 
requested in five patients and found to be positive in 
four. Anti Ro and Anti La antibodies was tested in three 
patients and found to be positive in one patient. 
 
Complement 3 and Complement 4 components of the 
complement pathway were tested in three patients and 
levels were within the normal range but low in one pa-
tient. All patients had urine tested for protein. Signifi-
cant proteinuria was found in three, and also significant 
numbers of red blood cells (rbcs) found in the urine of 
two patients during the course of pregnancy. The mean 
Hemoglobin level was 10.73g/dl (SD 1.41), mean plate-
let count was177 x 10 9 /l(SD 109.79), and mean White 
cell count was 4.98 x 10 9 /l(SD1.06). 
 
The Urine albumin:creatinine ratio was found to be sig-
nificantly raised in three patients. Urea and creatinine 
levels was found to be normal in all patients Two pa-
tients of the three had previous renal biopsies which 
showed Class III – Focal lupus nephritis (active and 
chronic; proliferative and sclerosing), and Class IV – 
Diffuse lupus nephritis (active and chronic; proliferative 
and sclerosing; segmental and global) lupus nephritis. 
One completed treatment with cyclophosphamide four 
years earlier and was in remission and one was sched-
uled for treatment when she got pregnant. 
 





























Joint pain Joint pain Joint pain, 
rash 







Hydroxychloroquine 200mg 200mg Nil 400mg 200mg 200mg Nil 
Azathioprine Nil Nil 75mg Nil 75mg Nil Nil 
Sol Aspirin 75mg 75mg Nil 75mg 75mg 75mg Nil 
Nifedipine 40mg bd Nil Nil Nil Nil Nil 30mg dly 
Amlodipine Nil Nil Nil Nil 5mg Nil Nil 
Methyldopa 500mg bd Nil Nil Nil 500mg bd Nil Nil 
Folic Acid 5mg 5mg 5mg 5mg  5mg 5mg 5mg 
















All patients were on immunosuppressive treatments 
during their pregnancy with prednisolone doses ranging 
from 10 - 60mg daily. One patient received pulsed 
Methylprednisolone three months prior to conception as 
part of the protocol for lupus nephritis and one after 
delivery for complications. Other treatments included 
Hydroxychloroquine, Azathioprine and Soluble Aspirin. 
 
Antihypertensive treatment used for those with high 
blood pressure (BP) was Nifedipine, Methyldopa, and 
one patient received Amlodipine briefly; this was 
switched to Methyldopa on confirmation of pregnancy. 
Outcome of pregnancy 
Four patients delivered normal healthy babies including 
one mother who had Anti Ro and Anti La antibodies. 
Three pregnancies were lost at various stages of preg-
nancy namely at weeks 32, 16 and 24. Two of these 
patients who lost their babies had significant pro-
teinuria, but all three who lost their babies had high BPs 
varying from 150/100 - 160/100. 
 
DISCUSSION 
The first rheumatology clinic at the Korle bu Teaching 
Hospital (KBTH) the premier teaching hospital in Gha-
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An audit of patients over a year from June 2011 to June 
2012 showed 226 newly diagnosed patients (excluding 
follow ups) were seen in the clinic, with Rheumatoid 
arthritis and SLE comprising majority of cases, i.e. 
89(39.3%) and 48(21.2%) respectively. 
 
This study consisted of only seven pregnancies in six 
patients with SLE. Though small it gives an encourag-
ing prospect for successful pregnancies in this group of 
patients who many doctors in Ghana have not had the 
experience to manage and may not know what to expect 
in this environment. It also provides preliminary data 
for future follow up. 
 
Most of the pregnancies were not planned with their 
doctors, underscoring the difficulty in delaying preg-
nancy in this group of patients in their reproductive ages 
who have the need to have children despite the difficul-
ties that it entails vis a vis their condition especially in 
the face of societal expectations to have children.  
 
Most of the patients had clinical and laboratory evi-
dence of active disease and ideally should not have been 
the right time for conception. Most studies and recom-
mendations in pregnancy in SLE recommend at least 6 
months of stable disease before pregnancy is planned to 
ensure good outcome for both the mother and fetus re-
garding disease activity and the chance of a successful 
pregnancy with minimal complications.12,13 
 
It is recommended that prenatal care be initiated at an 
institution where the obstetrician is experienced in the 
possible complications of lupus and where consultation 
with a rheumatologist is available.14 This was not the 
case in this entire group, though they thereafter had reg-
ular close follow up by the rheumatologist and obstetri-
cian and in some cases the nephrologists after concep-
tion.  
 
A major predictor of outcome of pregnancy in this study 
appears to be the level of the blood pressure. All pa-
tients who lost their pregnancy had high blood pressure 
both at conception and throughout the pregnancy this 
was not well controlled according to recommended tar-
gets. This correlates with the finding in other studies 
where the major determinants of a negative outcome 
have been high blood pressure, nephritis and the anti- 
phospholipid syndrome. Hypertensive complications in 
lupus increase the risk for preterm birth, intrauterine 
growth retardation (IUGR) and fetal loss.15,16 
 
 Preeclampsia and eclampsia can mimic lupus with both 
presenting with edema, thrombocytopenia, hyperurice-
mia, anemia, hypertension, proteinuria, renal impair-
ment, and hematuria and additionally seizures in ec-
lampsia.  The difficulty in distinguishing this was evi-
dent in one case who lost the fetus at 24 weeks, with 
signs and laboratory features suggestive of preeclamp-
sia, but also had features of active SLE with low com-
plements and the rare eye complication of macular de-
tachment that improved with pulsing of methylpredniso-
lone.  
 
The challenge to confidently differentiate if the patient 
is demonstrating a normal pregnancy sign, a hyperten-
sive complication associated with the pregnancy or a 
lupus flare was seen in this case and this was complicat-
ed with the difficulty of getting fast, accurate results in a 
limited resource setting. In these circumstances, the 
inclination is to over treat to safeguard the safety of the 
mother and fetus and have a successful pregnancy out-
come.16 The patient had treatment for both SLE flare 
and had a hysterotomy on account of preeclampsia. 
 
There was evidence of renal involvement in four out of 
the six patients, but only three were able to do their 
urine albumin ratios to quantify the protein levels. Ideal-
ly the antiphospholipid assay should be tested in all pa-
tents especially for those who have lost previous preg-
nancies as well as the anti Ro and Anti-La antibodies 
pre-conceptually to determine the risks associated with 
having these antibodies.  Monitoring should include 
baseline and monthly laboratory tests, serial ultrasonog-
raphy, fetal surveillance tests, and fetal m-mode echo-
cardiography for mothers with SS-A (Ro) or SS-B (La) 
antibodies.17 These were not available to our patients.    
One limitation of the study is that the high cost of tests 
limited our ability to run all tests on all patients.  
 
Treatments used for these patients included low dose 
prednisolone and in the case of one patient who had a 
severe flare IV methylprednisolone, hydroxychloro-
quine and azathioprine. In the absence of any signs or 
symptoms of active SLE, patients need no definite 
treatment during pregnancy.16 If hydroxychloroquine 
was in use before conception, it should be maintained 
throughout pregnancy. If a woman with SLE has an-
tiphospholipid antibodies, prophylactic treatment with 
aspirin and/or low-molecular weight heparin is indicated 
to prevent fetal loss. Two of the patients followed up 
here tested positive for antiphospholipid antibodies.. 
One patient who tested positive for antiphospholipid 
antibodies lost the pregnancy despite taking aspirin.   
Lupus flares during pregnancy were generally treated 
with hydroxychloroquine, low-dose prednisone, pulse 
intravenous methylprednisolone, and azathioprine.17 
 
All four babies delivered had normal APGAR scores 
and no birth deformities were recorded. There was no 
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restriction. All babies were well in the first three months 
of monitoring. 
 
There were four caesarian sections and three spontane-
ous vaginal deliveries (SVD) with no adverse outcome 
to mothers, but two deliveries by SVD died and one by 
caesarian section. Mothers remain stable and had neither 
complications nor SLE flares in the first three months 
after delivery.  Of the mothers who lost their pregnan-
cies two remained stable, one developed acute renal 
failure and macula detachment with visual impairment.  
These all normalized during the first three months of 
monitoring and treatment with pulse intravenous ster-
oids and mycophenolate mofetil. This is reassuring con-
sidering the resource limitations. 
 
Pre-pregnancy counselling and multidisciplinary man-
agement with other specialists such as the obstetricians 
and the perinatologists is crucial in improving the ma-
ternal and fetal outcome in lupus pregnancies, though 
such specialists are in short supply in a resource poor 
environment like Ghana. 
 
Conclusion and future 
These cases provide good evidence that pregnancy is 
possible in patients with SLE, even in resource poor 
settings though the numbers are small to make a definite 
conclusion on outcomes. There is the need to emphasize 
getting the condition in remission before conception and 
good control of blood pressure, which are associated 
with poor outcome. 
 
There is the need to train more health personnel to care 
for these complicated conditions. These case series 
would set in motion the collection of long-term data on 
pregnancy in lupus patients in Ghana to help understand 
the unique characteristics of patients in Ghana and sub-
Saharan Africa and may open the window to a greater 
understanding of the pathophysiology of these diseases. 
There are no conflict of interest reported by authors and 
no ethical approval was required. 
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